Emergent's 'We Go' ad campaign continues with latest ads featuring its military work (above) and Narcan generic opioid reversal agent.
January 18, 2022 07:06 PM ESTUpdated 06:45 PM
Pharma
Marketing

Emer­gent TV ads book­end its tu­mul­tuous year. Can mil­i­tary, Nar­can work help re­hab its brand?

Beth Snyder Bulik

Senior Editor

When the Covid-19 pan­dem­ic hit, Emer­gent BioSo­lu­tions was rel­a­tive­ly un­known. But the con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO) sud­den­ly hit the spot­light when it nabbed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times